Having trouble accessing articles? Reset your cache.

AZD1446: Phase IIa data

Top-line data from a double-blind, crossover, U.S. Phase IIa trial in 79 patients ages 18-65, including 27 nicotine and 52 non-nicotine users, showed that AZD1446 missed the primary endpoint of significantly improving core symptoms of ADHD

Read the full 368 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers